Eiger BioPharmaceuticals Inc EIGR

Healthcare Biotechnology

Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development of therapies for hepatitis delta virus (HDV) and other serious rare diseases. The Eiger HDV platform includes two therapies in phase III that target critical host processes involved in viral replication. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV and Covid-19, Avexitide in Congenital Hyperinsulinism (HI) and Avexitide in Post-Bariatric Hypoglycemia (PBH). Zokinvy (lonafarnib) for Hutchinson-Gilford progeria syndrome (HGPS) and Processing-Deficient Progeroid Laminopathies (PL) is its approved product. LNF is an orally bioavailable, farnesylation inhibitor in a phase III clinical trial for HDV infection and is its lead program. Lambda is its second program in clinical development for HDV and Covid-19, which is in phase III. Zokinvy is used to reduce the risk of mortality in HGPS and to treat processing-deficient PL.

NDAQ:EIGR - Post by User

Eiger BioPharmaceuticals Inc

Bullboard Posts

Comment by stockfloweron Jul 14, 2017 7:17pm

222 Views

Post# 26471702

RE:200 Day Moving Average is 0.13 Cents Away!

Current high price on July 16, 2017 was 10.25 p/s while the 200 day moving average is 10.38 p/s. That is price difference of 0.13 cents that needs to be gained to break the 200 day MA. BTIG Research initiated coverage on Eiger BioPharmaceuticals with a Buy rating and a $32.00 price target. I remain hopeful.

Bullboard Posts

One of the strongest contenders to lead Canada’s cannabis market